Squamous Cell Cancer Clinical Trial
Official title:
The Clinical Utility of PET-CT in the Management of Squamous Cell Carcinoma of the Neck Nodes With Unknown Primary Malignancy
| NCT number | NCT00530283 |
| Other study ID # | 20682 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | August 2007 |
| Est. completion date | July 2010 |
| Verified date | August 2011 |
| Source | AHS Cancer Control Alberta |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Patients with squamous cell cancer of neck nodes but unknown primary will have a PET-CT scan prior to biopsies. The utility of PET-CT will be determined in this subset of patients.
| Status | Completed |
| Enrollment | 20 |
| Est. completion date | July 2010 |
| Est. primary completion date | July 2010 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - squamous cell cancer of neck nodes with unknown primary site Exclusion Criteria: - unable to tolerate PET-CT - unable to undergo examination under anaesthesia |
| Country | Name | City | State |
|---|---|---|---|
| Canada | Tom Baker Cancer Centre | Calgary | Alberta |
| Lead Sponsor | Collaborator |
|---|---|
| AHS Cancer Control Alberta | Calgary Health Region, University of Calgary |
Canada,
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01358097 -
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
|
N/A | |
| Completed |
NCT00705016 -
Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04116320 -
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01721525 -
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
|
Phase 1 | |
| Completed |
NCT01016769 -
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
|
Phase 1/Phase 2 | |
| Completed |
NCT00661427 -
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
|
Phase 2 | |
| Completed |
NCT00382031 -
Zalutumumab in Patients With Non-curable Head and Neck Cancer
|
Phase 3 | |
| Recruiting |
NCT04391049 -
Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
|
Phase 1 | |
| Recruiting |
NCT05932511 -
Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer
|
Early Phase 1 | |
| Not yet recruiting |
NCT06398418 -
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT00815295 -
Study of Sorafenib/Cetuximab in Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00542308 -
Zalutumumab in Non-curable Patients With SCCHN
|
Phase 2 | |
| Completed |
NCT00485485 -
Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
|
Phase 2 | |
| Terminated |
NCT02376699 -
Safety Study of SEA-CD40 in Cancer Patients
|
Phase 1 | |
| Completed |
NCT00255476 -
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
|
Phase 2 | |
| Recruiting |
NCT03935893 -
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
|
Phase 2 | |
| Terminated |
NCT00401401 -
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT00559351 -
RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus
|
Phase 3 | |
| Active, not recruiting |
NCT03370276 -
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03509467 -
Using MC1R Genotype to Impact Melanoma Risk Behavior
|
N/A |